Vydelingum Named Deputy Director of NCI Center
Dr. Nadarajen A. Vydelingum has been named deputy director of the NCI Center to Reduce Cancer Health Disparities. He has experience in both clinical research and basic science and brings a diverse background in education and administration to the position. The center's goal is to translate research discoveries into policies and/or services aimed at reducing cancer-related health disparities in racial, ethnic, elderly and medically underserved communities. Vydelingum earned a Ph.D. in clinical biochemistry from London University. In 1977, he began his career in the United States at the Medical College of Wisconsin in the departments of medicine and pharmacology and as director of the lipid laboratory in the General Clinical Research Center. His early research interest in insulin action and fat metabolism as related to type II diabetes and obesity attracted him to Memorial Sloan-Kettering Cancer Center in New York, where he led a group on the study of cancer cachexia (cancer-induced tissue depletion) and the influence of cytokines on lipid/protein stores in cancer patients. In 1991, Vydelingum joined the Division of Research Grants (now CSR) where he headed a scientific review group on peer review in bioengineering and physiology. He has a major interest in science education. He has organized courses for target M.D. students and for students of biochemistry at the Foundation for Advanced Education in the Sciences and spent 3 years as lecturer in advanced cell biology at Johns Hopkins University. He has reviewed more than 200 science books for Northeastern and Boston universities and participates in outreach programs organized by the NIH Speaker's Bureau.
Politis Heads Group at CSR
Dr. Alexander Politis is the new chief of the infectious diseases and microbiology integrated review group at the Center for Scientific Review. He previously was scientific review administrator of CSR's immunological sciences study section. Politis earned his Ph.D. in cell biology from the University of Maryland, where he studied the mechanisms of cell volume regulation. At the Uniformed Services University of the Health Sciences, he studied signal transduction and gene regulation related to the activation of murine macrophages by interferons. He then moved to Human Genome Sciences, Inc., where he evaluated recombinant proteins discovered through sequenced cDNA clones for their ability to activate monocytes. Before coming to CSR, he was assistant editor of the Journal of Immunology.
Armstrong Leads CSR Review Group
Dr. David Armstrong has been named chief of the brain disorders and clinical neuroscience integrated review group at the Center for Scientific Review. He recently was the principal investigator on three NIH grants to study transmitter neuroanatomy and the GABA receptor in Alzheimer's disease. Armstrong has devoted his career to understanding the cellular and molecular mechanisms related to the neurodegeneration seen in Alzheimer's and stroke patients. He has authored or coauthored more than 90 journal articles, advancing the understanding of the neurotransmitter systems and gene products associated with the neuronal vulnerability that precedes neurodegeneration. His academic and administrative experiences include serving as senior scientist and associate director of the Lankenau Institute for Medical Research; professor and associate director of the Institute on Aging at the MCP-Hahnemann School of Medicine; associate professor at Georgetown University Medical College; and assistant professor at the University of California in San Diego and the Albert Einstein College of Medicine.
Up to Top